Juno Therapeutics, Editas Medicine collaborate on cancer therapies
Juno Therapeutics, a Seattle-based biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, and Editas Medicine, a Camrbidge, Mass.-based genome editing company, are collaborating on creating chimeric antigen receptor (CAR T) and high-affinity T cell receptor (TCR) therapies to treat cancer. The companies will pursue three research programs together utilizing Editas’ genome editing technologies, including CRISPR/Cas9, with Juno’s CAR and TCR technologies.
Juno will pay Editas an upfront payment of $25 million and up to $22 million in research support over the next five years across the three programs in the alliance. Editas also is eligible to receive future research, regulatory and commercial sales milestones in excess of $230 million for each program. Following the approval of any products resulting from the alliance, Editas also is eligible to receive tiered royalties.